Goldline Pharmaceutical share price
BSE: 544759Pharmaceuticals & BiotechnologySmall Cap
GOLDLINE PHARMACEUTICAL LIMITED · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2026
Last close ₹30.50down ₹2.48 (7.52%)
Share price at the BSE close on 28 Oct 2026. Previous close ₹32.98.
28 Oct: open ₹30.50, high ₹30.50, low ₹30.50
Range of traded prices from listing on 19 May 2026 to 28 Oct 2026
₹28.13Low, 21 Oct 2026₹60.00High, 19 May 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹29 Cr3,537th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 7.11
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.05
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in May 2026
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 28.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.64
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 3,000
Results
Standalone; ₹ crore.Goldline Pharmaceutical half-yearly results
Half year to Mar 2026, against the half year before
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹17 Crup 24.57%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹2.76 Crup 103.70%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 16.0%
Revenue by half year
Peak revenue ₹17 Cr, half year to Mar 2026; lowest ₹14 Cr, half year to Sep 2025
Net profit by half year, a loss in red
| ₹ crore | Sep 2025 | Mar 2026 |
|---|---|---|
| Revenue | 13.9 | 17.3 |
| Net profit | 1.4 | 2.8 |
| Net margin | 9.8% | 16.0% |
Standalone. The 2 half years from Sep 2025, the first on record. The latest is shaded.
Year to Mar 2026
- Revenue
- ₹31 Cr
- Net profit
- ₹4.12 Cr
- Net margin
- 13.2%
| ₹ crore | Mar 2026 |
|---|---|
| Revenue | 31.2 |
| Net profit | 4.1 |
| Net margin | 13.2% |
Standalone. Years to March.
Business segments
In the year to Mar 2026 the company reports one business segment, Wholesale trade of Pharmaceuticals, which carries all its revenue.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Goldline Pharmaceutical insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group4 purchases, 0 sales₹0.26 Cr3 mores with no value filedNo saleNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.₹0.26 Crof the trades with a value
- Directors and key managers1 purchase, 0 salesValue not statedNo saleNetValue not stated
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Goldline Pharmaceutical competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Goldline Pharmaceutical in market cap. 1 company in the table last traded before then: its row is priced on its last trade.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Roopa IndustriesROOPAIND | 34 | 261.57 | 1.90 | +3.7% | −93.7% | 0.7% | 15.4% | 0.00% |
 Jfl Life SciencesJFLLIFE | 33 | 4.87 | 0.72 | – | – | 15.9% | 15.9% | 0.00% |
 Gujarat Terce LaboratoriesGUJTERC | 33 | 15.59 | 3.35 | −7.2% | – | 25.8% | 25.8% | 0.00% |
 Medi CapsMEDICAPQ | 31 | – | 0.28 | −42.9% | – | −1.5% | −8.7% | 0.00% |
 Sunrest LifescienceSUNREST | 29 | 6.98 | – | – | – | 22.4% | – | 0.00% |
 Bacil PharmaBACPHAR | 28 | – | 1.10 | – | – | – | −0.7% | 0.00% |
 Welcure Drugs & PharmaceuticalsWELCURE | 23 | – | – | – | – | – | – | 0.00% |
 Walpar NutritionsWALPAR | 23 | 9.49 | 1.24 | +9.8% | −42.7% | 14.0% | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Goldline Pharmaceutical announcements
Sep 2026
Aug 2026
31 Aug · Meeting
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 27 Oct 2026 | 31.89 | 32.98 | 31.89 | 32.98 | 32.19 | 12,000 |
| 26 Oct 2026 | 31.99 | 31.99 | 31.99 | 31.99 | 31.99 | 3,000 |
| 23 Oct 2026 | 30.10 | 30.10 | 30.10 | 30.10 | 30.10 | 6,000 |
| 21 Oct 2026 | 30.00 | 30.30 | 28.13 | 29.98 | 29.63 | 27,000 |
| 19 Oct 2026 | 32.01 | 32.01 | 32.00 | 32.00 | 32.01 | 6,000 |
| 16 Oct 2026 | 32.00 | 32.48 | 32.00 | 32.48 | 32.24 | 6,000 |
| 15 Oct 2026 | 32.99 | 32.99 | 31.56 | 31.56 | 32.27 | 6,000 |
| 14 Oct 2026 | 31.18 | 34.82 | 31.18 | 31.68 | 32.56 | 9,000 |
| 13 Oct 2026 | 32.50 | 32.50 | 32.50 | 32.50 | 32.50 | 6,000 |
Prices in ₹ per share as traded, not adjusted.
Company details
- BSE code
- 544759
- ISIN
- INE1CLW01015
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.goldlinepharma.in
- Registered office
- Plot No.103 , F-1, Leela Apartment, Near Shanidham Mandir , Saptagiri Nagar, Narendra Nagar, Nagpur 440015, Maharashtra
- Share registrar
- Bigshare Services Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In BSE SME IPO